- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00252577
Genetic Predictors of Lithium Response in Bipolar Disorder
January 17, 2020 updated by: VA Office of Research and Development
Genetic Studies of Psychiatric Illness
The purpose of this study is to identify genetic predictors of lithium response in bipolar disorder.
Study Overview
Detailed Description
The long term focus of this research program has been identification of genes for bipolar disorder.
The investigators have recently obtained evidence from several lines of investigation to support the role of the gene for G protein receptor Kinase 3(GRK3) in bipolar disorder.
Work to replicate and extend these results is continuing under NIH funding.
In this clinical the investigators will extend the investigators' work into Pharmacogenetics to attempt to identify genes that are associated with medication response in bipolar disorder.
Lithium is the first mood stabilizer medication and remains a mainstay of treatment.
Many patients have an excellent response to lithium, tolerate it well, and are stabilized for years, while others do not.
The reasons for this difference in response are unclear, but it is likely that genetic factors make a substantial contribution.
The lack of good predictors of response frequently result in a time consuming trial and error clinical process to find the best medication.
Such a trial and error process can take months with prolongation of patient suffering.
Hence, there is a strong clinical need for predictors.
The investigators have conducted a preliminary study with 92 lithium responders and 92 non-responders identified through retrospective detailed history and chart review.
These subjects have been genotyped at 88 single nucleotide polymorphism (SNP) markers in 9 candidates genes relevant to lithium presumed mechanism of action for bipolar disorder.
Four SNP markers in three genes showed nominally significant association to lithium response.
One of the SNPs in the gene for neurotrophic receptor tyrosine kinase 2 (NTRK2), the receptor for brain-derived neurotrophic factor (BDNF), showed a strong association in patients who had predominantly euphoric a opposed to dysphoric mania (p=0.0005).
Many data argue for the role of BDNF in the mechanism of antidepressants and mood stabilized action as well as susceptibility to bipolar disorder.
No association was observed in those with dysphoric mania.
This suggests that variations in this gene may operate in a clinically and genetically distinct subset of patients.
It also argues for the importance of incorporating clinical subtypes into such analyses.
These pilot results are preliminary but suggest the feasibility of such an approach.
The investigators will conduct a prospective trial of lithium monotherapy in 100 patients with bipolar disorder.
200 patients who are unstable, mildly to moderately ill and not on lithium will be screened and then entered into 16-week stabilization phase where they will be treated and switched to lithium monotherapy.
Patient stable on lithium will also be entered and other mediations withdrawn.
After stabilization patients will be followed for one year or until a mood episode requires intervention.
It is expected that 50% of patients will be stabilized and therefore 100 patients will enter the maintenance phase.
Time to relapse and pharmacological intervention will be the primary outcome measure.
This prospective sample will be used to replicate previous results at the NTRK2 and other genes.
Analyses will be conducted to test for differences in survival curves between different genotypic group.
Genomic control methods will be employed to detect or correct for possible stratification and heterogeneity.
Clinical features of illness such as dysphoric mania, family history and rapid cycling will be employed as co-variates.
Multivariate methods will also be employed in order to attempt to develop a multi-gene predictor of lithium response.
Study Type
Observational
Enrollment (Actual)
130
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92161
- VA San Diego Healthcare System, San Diego, CA
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Veterans with bipolar disorder
Description
Inclusion Criteria:
- Are 18 years of age or older;
- Have a diagnosis of Bipolar Affective Disorder, I or II;
- Have no contraindications, allergies, or previous adverse events or treatment failures with lithium;
- Women who are not currently pregnant and are willing and able to use birth control;
- Are clinically appropriate to treat with lithium.
Exclusion Criteria:
- DSM-IV Axis I Diagnosis: other primary comorbid axis I disorders such as: schizophrenia, schizoaffective disorder, delusional disorder;
- Alcohol or Substance Dependence: meets criteria for dependence within past 3 months;
- Unstable Medial Conditions: Life threatening or unstable medical condition that require active adjustment of medications by medical history; or
- Medical Conditions: concomitant medical condition that would preclude the use of lithium (i.e.: renal failure, head trauma with loss of consciousness, or clinically significant cardiac, renal, hepatic, neoplastic, or cardiovascular disease);
- Concomitant treatment with the following medications (during maintenance Phase): antipsychotics, antidepressants, antianxiety agent with the exception of benzodiazepines, to be used if needed for anxiety or insomnia, not to exceed 10 doses/week, or mood stabilizers with the exception of lithium; and
- Active suicidal or homicidal ideations as elicited in the interviews.
- Stable and doing well on a mood stabilizer other than lithium.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
Veterans with bipolar disorder
|
Lithium is a standard treatment for bipolar disorder.
Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Relapse
Time Frame: every 2 months for 2 years
|
The primary outcome measure was time to relapse in months following stabilization on lithium.
|
every 2 months for 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: John R Kelsoe, MD, VA San Diego Healthcare System, San Diego, CA
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2005
Primary Completion (ACTUAL)
March 1, 2016
Study Completion (ACTUAL)
May 1, 2016
Study Registration Dates
First Submitted
November 9, 2005
First Submitted That Met QC Criteria
November 9, 2005
First Posted (ESTIMATE)
November 11, 2005
Study Record Updates
Last Update Posted (ACTUAL)
January 29, 2020
Last Update Submitted That Met QC Criteria
January 17, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MHBA-023-05S
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
Clinical Trials on Lithium treatment
-
University of ValenciaRecruitingOutcome | Wear, Tooth | Dental Wear | ProstheticSpain
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
China Spinal Cord Injury NetworkChengdu PLA General Hospital; StemCyte, Inc.Completed
-
Peking UniversityUnknownthe Use of Antidepressants in Patients With Bipolar DepressionChina
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
University of CincinnatiUnknownBipolar I DisorderUnited States
-
National Institute of Mental Health (NIMH)CompletedEffectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder (LiTMUS)Bipolar DisorderUnited States
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
University of Maryland, BaltimoreCompletedOsteoporosis PseudogliomaUnited States
-
Northwestern UniversityCompletedBipolar DisorderUnited States